This FTSE 100 stock has 34 years of dividend increases and trades at a 52-week low

Buying shares in a durable business at an unusually low price is what investors dream of. And a FTSE 100 company might give them that chance.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Middle aged businesswoman using laptop while working from home

Image source: Getty Images

Every business goes through ups and downs, but not many can increase their dividend every year since 1991. But that’s the case with one FTSE 100 stock that’s trading at a 52-week low.

Croda International (LSE:CRDA) is a chemicals company that’s been going through tough times of late. But this is a firm that has seen it all before.

Cyclical lows

Croda’s increased its dividend per share every year since 1991, which is almost as long as I’ve been alive. And a lot has happened in that time. The last 34 years have included the dot-com crash in 2000, the 2008-2009 Great Financial Crisis, and – of course – Covid-19. But none of these have stalled the FTSE 100 firm’s dividend growth.

What makes this even more impressive, in my view, is the underlying business is quite cyclical. Demand for its products can fluctuate substantially in different economic environments.

With this type of business, the stock market can be prone to overreactions. So the key is to find a way to buy it when it’s cheap and avoid it when it’s expensive. 

By most metrics, the stock looks like it’s unusually good value at the moment. It’s at a 52-week low and the dividend yield’s the highest it’s been in a decade. As a result, I think investors should consider adding the stock to their watchlists. At the very least, I think it’s worth a closer look. 

Cyclical valuation

Croda International makes chemicals for the cosmetics, agriculture, and life sciences industries. So demand can wax and wane depending on how these end markets are faring.

The company’s ability to influence this is obviously limited. And that makes the cyclical nature of its end markets a risk for investors, which has been manifesting itself recently. Over the last couple of years, Croda’s been battling elevated inventory levels, especially in the agriculture sector. As a result, sales and profits have been falling.

The stock currently trades at a price-to-earnings (P/E) ratio of around 27. That looks high – and it is – but if earnings per share get back to their 2017 levels, that will fall to around 17.

Croda’s patents and the fact its products are often specified by regulation mean I expect this to happen sooner or later. And while investors wait, there’s a dividend with a 3.75% yield.

Importantly, the dividend is well-covered by the company’s earnings. And I think that means there’s a good chance of the long track record of rising distributions continuing this year.

Long-term investing

In the short term, there are macroeconomic indicators investors look at to try and work out when demand will pick up. But with a stock like Croda International, I’m not sure it’s worth it.

I think the better move for investors is to take the long-term view. This is a business that has seen it all before and kept moving forward throughout. On top of this, the company has durable competitive strengths and operates in an industry where demand is at a cyclical low. At a 52-week low, I think it’s worth considering.

Stephen Wright has no position in any of the shares mentioned. The Motley Fool UK has recommended Croda International Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Middle-aged white man pulling an aggrieved face while looking at a screen
Market Movers

Down 7%! Why on earth are Imperial Brands shares plummeting today?

Imperial Brands shares are in freefall after a negative reception to fresh trading news. Is the party finally over for…

Read more »

Rear View Of Woman Holding Man Hand during travel in cappadocia
Investing Articles

With a P/E under 7, this value stock looks far too cheap at 101p

This writer reckons value stock Hostelworld (LSE:HSW) looks dirt-cheap as it gets dividends flowing again and builds a social travel…

Read more »

Thoughtful man using his phone while riding on a train and looking through the window
Investing For Beginners

Down 30% in 6 months, I think there’s a big catch to this insanely cheap stock

Jon Smith talks through why careful research is needed when trying to assess if a cheap stock is worth buying…

Read more »

Investing Articles

£5,000 invested in National Grid shares 5 years ago is now worth…

Andrew Mackie takes a closer look at National Grid shares and why short-term market weakness could be missing a powerful…

Read more »

DIVIDEND YIELD text written on a notebook with chart
Investing Articles

How big does an ISA need to be to aim for a £1,500 monthly second income?

Harvey Jones shows how building a balanced portfolio of FTSE 100 dividend stocks can produce a high-and-rising second income in…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

£20,000 invested in BP shares 1 year ago is now worth…

BP shares have rocketed in the past 12 months, yet analysts think the real growth story is only just beginning,…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

A 6.8% forecast yield! 1 often-overlooked FTSE 100 income stock to buy today?

This income stock offers a high forecast yield and strengthening momentum, yet many investors overlook it — creating a rare…

Read more »

GSK scientist holding lab syringe
Investing Articles

GSK’s share price is under £22, but with a ‘fair value’ much higher, is it time for me to buy more right now? 

GSK’s share price rose over the last year, but a huge gap remains between its price and fair value —…

Read more »